Why Is ACADIA PHARMACEUTICA (ACAD) Stock Up Today?
By the Top Tier Newswire AI Desk · November 10, 2026 at 3:56 PM ET · reviewed against 4 wire stories
ACADIA PHARMACEUTICA (ACAD) is up +11.12% in the latest session. Our newswire has captured 4 stories on ACAD across 3 sources in the last 36 hours, with AI sentiment reading mixed (avg 56/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Acadia Pharmaceuticals shares surged 11.12% to $18.34 on Monday. The primary driver was the Federal Circuit Court of Appeals hearing oral arguments in a patent dispute concerning the company’s lead drug, Nuplazid. The stock also benefited from an announcement that it will present new data for remlifanserin at an upcoming Alzheimer’s disease conference.
What Happened
The Federal Circuit heard oral arguments regarding an appeal in the Nuplazid formulation patent case. Acadia expects a decision in the first half of 2027. The company also announced it will present remlifanserin data at the 2026 Clinical Trials on Alzheimer’s Disease Conference. Deutsche Bank adjusted its price target for the stock to $30.
What The Data Shows
The stock opened at $16.51 and traded as low as $16.31 at 9:00 AM ET. It reached a session high of $18.39 at 3:55 PM ET before closing near that level at $18.38. Trading volume reached 4.5 million shares, which is 2.5 times the three-month daily average. Over the last eight sessions, the stock had declined 20.5% from $20.76 to $16.50. The 52-week range is $15.86 to $30.96. The company has a market cap of $3.7 billion, a P/E ratio of 7.9, and revenue growth of 14.8% over the trailing twelve months. The net margin stands at 30.1% with a beta of 0.89. Mark C. Schneyer, the Executive Vice President and Chief Financial Officer, sold shares on October 30, 2026. Donald J. Trump disclosed a sale of $15,001 to $50,000 on July 29, 2026.
What To Watch
Investors will monitor the Federal Circuit’s decision in the Nuplazid patent appeal, which is expected in the first half of 2027. The company’s presentation of remlifanserin data at the 2026 CTAD Conference will also be a key catalyst.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
ACAD · Nov 10 session (5-min) · +9.09% vs prior close · updated 8:51 PM ETAI sentiment, last 36h · averaged over 4 stories · 56/100 bullish
The headlines behind the move
Story flow · 4 stories on the wire, last 36h · hover or tap a dot for the headline
3d agoSeeking AlphaBULLISH 58General
Acadia gains after oral arguments in Nuplazid patent dispute
Acadia Pharmaceuticals (ACAD) stock gains as an appeal court hears oral arguments regarding a patent dispute related to its lead drug, Nuplazid. Read more here.
3d agoThe FlyBULLISH 56Product/PR
Acadia Pharmaceuticals to present Remlifanserin data at CTAD
3d agoStockTitanNEUTRAL 52General
Acadia Pharmaceuticals Comments on Federal Circuit Oral Argument in NUPLAZID® Formulation Patent Appeal
4d agoStockTitanBULLISH 58Product/PR
Acadia Pharmaceuticals to Present Remlifanserin Data at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) Conference
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →